Crinetics Pharmaceuticals, Inc.
CRNX
Classifica tra le azioni
#2241
Crinetics Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical... Crinetics Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical enterprise, dedicated to the identification, advancement, and market introduction of therapeutic solutions for infrequent endocrine conditions and related tumors. Their flagship drug candidate, Paltusotine, is an orally administered, selective, non-peptide somatostatin receptor type 2 agonist. This compound has concluded its Phase III clinical trials for the treatment of acromegaly, and has also completed Phase II trials targeting carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). Furthermore, the company's pipeline includes CRN04777, an oral selective non-peptide somatostatin type 5 receptor agonist, which is currently undergoing Phase I clinical trials for congenital hyperinsulinism. Another investigational drug, CRN04894, an oral adrenocorticotrophic hormone antagonist, is in Phase I clinical trials for Cushing's disease and congenital adrenal hyperplasia. Crinetics Pharmaceuticals, Inc. was founded in 2008 and maintains its headquarters in San Diego, California.
Prezzo delle azioni
$84.95
Ultima sincronizzazione: 2026-09-01
Capitalizzazione di mercato
$9.00B
Variazione (1 giorno)
0.00%
Variazione (1 anno)
104.35%
Paese
US
Scambia Crinetics Pharmaceuticals, Inc. (CRNX)
Categoria
Healthcare
EPS per Crinetics Pharmaceuticals, Inc. (CRNX)
EPS al June 2026 TTM: $-5.05
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di Crinetics Pharmaceuticals, Inc., l’EPS attuale della società (TTM) è $-5.05. Alla fine del 2023, la società aveva un EPS di $-3.69 un aumento rispetto a rispetto a quello del 2022, che era di $-3.15.
Storico EPS per Crinetics Pharmaceuticals, Inc. da 2016 a 2026
EPS alla fine di ogni anno
| Anno | EPS | Cambia |
|---|---|---|
| 2026 (TTM) | $-5.05 | 36.86% |
| 2024 | $-3.69 | 0.00% |
| 2023 | $-3.69 | 17.14% |
| 2022 | $-3.15 | 12.50% |
| 2021 | $-2.80 | 15.70% |
| 2020 | $-2.42 | 18.05% |
| 2019 | $-2.05 | -8.07% |
| 2018 | $-2.23 | 237.88% |
| 2017 | $-0.66 | 53.49% |
| 2016 | $-0.43 | 0.00% |
EPS per aziende simili o concorrenti
| Azienda | EPS | Differenza di EPS | Il paese |
|---|---|---|---|
| $17.32 | -442.97% |
US
|
|
| $-7.98 | 58.02% |
US
|
|
| $-5.29 | 4.75% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -649.31% |
NL
|
